Flurocitabine exhibits antitumor activity in Phase I studies for acute leukemia and solid tumors; it is a fluorinated anhydride analog of cytarabine that is partially hydrolyzed in vivo to two active antitumor metabolites: arabinosyl-fluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU).